Apr 06, 2021 4:05pm EDT Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021
Mar 04, 2021 8:30am EST Sapience Therapeutics to Present at the Upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley
Aug 19, 2020 8:30am EDT Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute
Aug 12, 2020 8:30am EDT Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors
Jun 17, 2020 8:30am EDT Sapience Therapeutics to Present Data on its Two Lead Programs at 2020 AACR Virtual Annual Meeting II
Jun 02, 2020 8:30am EDT Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications
May 07, 2020 8:30am EDT Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1/2 Trial of Lead Candidate ST101 in Advanced Cancer Indications
